ReviewExperimental & molecular medicine2026
Golgi dysfunction in Alzheimer disease: from human multiomic signatures to therapeutic targets.
Review in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deciphering the intricate pathogenesis of Alzheimer disease (AD) has been a highly demanding task for researchers for decades. Evidence from from human multiomic studies provides critical insights into complex disease mechanisms and drives novel findings. However, the data are often selectively comprehended, leaving a few notable factors underappreciated in the research field. We focus on the Golgi apparatus, one of the most undervalued organelles in AD research, to demonstrate its multidimensional contribution to the pathogenesis. Given the importance of Golgi in modulating intracellular protein and lipid homeostasis, implication of Golgi in AD pathogenesis deserves thorough investigation. In this review, we describe changes in Golgi morphology and function in AD, and summarize specific Golgi-related factors discovered by genomic, transcriptomic, proteomic, and lipidomic data using human samples. Based on the findings, we demonstrate mechanistic link of Golgi-related factors to AD pathogenesis and highlight potential therapeutic strategies to modify Golgi-mediated pathogenesis. Overall, Golgi dysfunction may serve as a notable mechanistic hub of AD pathogenesis, making it a promising target for development of novel therapeutic strategies.
Identifiers
42827109What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.